These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
714 related articles for article (PubMed ID: 25123222)
21. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). Ferdinand KC; Nasser SA Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408 [TBL] [Abstract][Full Text] [Related]
22. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
23. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
24. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9. Constantinides A; Kappelle PJ; Lambert G; Dullaart RP Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679 [TBL] [Abstract][Full Text] [Related]
26. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332 [TBL] [Abstract][Full Text] [Related]
27. Effects of lipoprotein apheresis on PCSK9 levels. Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324 [TBL] [Abstract][Full Text] [Related]
28. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Farnier M Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378 [TBL] [Abstract][Full Text] [Related]
29. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia. Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725 [TBL] [Abstract][Full Text] [Related]
30. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349 [TBL] [Abstract][Full Text] [Related]
31. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463 [TBL] [Abstract][Full Text] [Related]
32. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346 [TBL] [Abstract][Full Text] [Related]
33. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Tavori H; Giunzioni I; Linton MF; Fazio S Circ Res; 2013 Dec; 113(12):1290-5. PubMed ID: 24122718 [TBL] [Abstract][Full Text] [Related]
35. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045 [TBL] [Abstract][Full Text] [Related]
36. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350 [TBL] [Abstract][Full Text] [Related]
38. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916 [TBL] [Abstract][Full Text] [Related]
39. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease. Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756 [TBL] [Abstract][Full Text] [Related]
40. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors]. Avci A; Demir K; Altunkeser BB Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]